Summary & Overview

Acute Myocardial Infarction, Discharged Alive with MCC: Inpatient Reimbursement Overview

DRG 280 encompasses acute myocardial infarction cases discharged alive with one or more Major Complication or Comorbidity, indicating higher clinical complexity and resource use. Proper assignment affects inpatient reimbursement under the Medicare Severity Diagnosis-Related Group payment methodology because the Major Complication or Comorbidity status elevates the payment relative to less complex myocardial infarction admissions.

Acute Myocardial InfarctionDRG Acute Myocardial Infarction, Discharged Alive with MCCDRG 280Diagnosis-Related GroupInpatient ReimbursementMedicareCardiologyCoronary CareHospital CodingRevenue Cycle

DRG 280 Overview

DRG 280 covers inpatient admissions for acute myocardial infarction in patients who survive to discharge and have one or more Major Complication or Comorbidity present. This Diagnosis-Related Group reflects higher resource intensity due to severe cardiac complications or significant comorbid conditions that require additional diagnostics, monitoring, and therapeutic interventions. It matters for Medicare payment because the presence of a Major Complication or Comorbidity adjusts the relative weight and reimbursement level under the inpatient prospective payment system. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and thereby influence Medicare inpatient reimbursement.

National Payment Rates

Across commercial payers the negotiated rate range for DRG 280 spans from roughly $15K (BCBS median) up to about $60K (Anthem max), with means clustering near the mid-$20K range; the widest spread is seen with Anthem (min-to-max up to $60K). See the payer table and accompanying chart below for payer-level percentiles and distribution comparisons. Payer variability highlights differences between national commercial contracts and Medicare benchmarks.

Mean Rates by Payer — National — DRG 280

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

For DRG 280 in Alaska, mean rates range from $25K (Anthem and Blue Cross Blue Shield) up to $39K (Cigna), showing a wide payer spread within the state. The most notable deviation from national averages is Cigna’s higher mean reimbursement, which sits well above the state’s other payers and several national medians. See the table and chart below for the payer-specific distributions.

Key Insights for Alaska

Highest payer: Cigna (mean $39K); Lowest payers: Anthem and Blue Cross Blue Shield (mean $25K).
Cigna’s mean in Alaska (~$39K) is notably above the provided national medians for several national payers, representing a meaningful upward deviation from the state’s other payers.

Clinical Trials

Acute-phase reperfusion and complication-reduction trials: studies that evaluate timing, strategies, and adjunctive therapies for reperfusion in patients presenting with acute ST-elevation or high-risk non–ST-elevation myocardial infarction complicated by major comorbid conditions (eg, cardiogenic shock, heart failure, or significant renal dysfunction). These trials enroll patients during the initial hospitalization to compare immediate intervention approaches, procedural timing, or periprocedural management aimed at reducing in-hospital mortality and major complications. Findings inform inpatient protocols, resource utilization, and short-term payment episodes for high-acuity AMI patients with major complications.
Comparative effectiveness and risk-stratified management studies: pragmatic trials or observational effectiveness research that compare evidence-based inpatient care bundles, antithrombotic strategies, or care pathways across subgroups defined by age, multimorbidity, or frailty among AMI patients with major complications. These studies focus on which real-world approaches lead to lower length of stay, readmission risk, and complication rates in complex patients, helping providers choose cost-effective care models and payers design value-based reimbursement for high-cost DRG 280 cases.
Post-discharge transitional care and secondary prevention outcomes research: studies that follow high-risk survivors of an AMI hospitalization with major complications to test models of care coordination, medication adherence interventions, cardiac rehabilitation access, and remote monitoring aimed at reducing 30- and 90-day readmissions and mortality. These trials or cohort studies target discharged-alive patients grouped under this DRG to identify interventions that improve long-term outcomes and lower downstream utilization, directly relevant to bundled payment programs and post-acute care planning.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$14K	$73K	$12K	87K

Acute-phase reperfusion and complication-reduction trials: studies that evaluate timing, strategies, and adjunctive therapies for reperfusion in patients presenting with acute ST-elevation or high-risk non–ST-elevation myocardial infarction complicated by major comorbid conditions (eg, cardiogenic shock, heart failure, or significant renal dysfunction). These trials enroll patients during the initial hospitalization to compare immediate intervention approaches, procedural timing, or periprocedural management aimed at reducing in-hospital mortality and major complications. Findings inform inpatient protocols, resource utilization, and short-term payment episodes for high-acuity AMI patients with major complications.
Comparative effectiveness and risk-stratified management studies: pragmatic trials or observational effectiveness research that compare evidence-based inpatient care bundles, antithrombotic strategies, or care pathways across subgroups defined by age, multimorbidity, or frailty among AMI patients with major complications. These studies focus on which real-world approaches lead to lower length of stay, readmission risk, and complication rates in complex patients, helping providers choose cost-effective care models and payers design value-based reimbursement for high-cost DRG 280 cases.
Post-discharge transitional care and secondary prevention outcomes research: studies that follow high-risk survivors of an AMI hospitalization with major complications to test models of care coordination, medication adherence interventions, cardiac rehabilitation access, and remote monitoring aimed at reducing 30- and 90-day readmissions and mortality. These trials or cohort studies target discharged-alive patients grouped under this DRG to identify interventions that improve long-term outcomes and lower downstream utilization, directly relevant to bundled payment programs and post-acute care planning.

OpenPayer

Summary & Overview

Acute Myocardial Infarction, Discharged Alive with MCC: Inpatient Reimbursement Overview

DRG 280 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes